DOVATO Dosing
A Complete Single-Tablet Regimen Offering
USE IN SPECIFIC POPULATIONS (RENAL IMPAIRMENT)
DOVATO IS NOT RECOMMENDED IN PATIENTS WITH CREATININE CLEARANCE <30 mL/min. BECAUSE DOVATO IS A FIXED-DOSE TABLET, IT CANNOT BE DOSE ADJUSTED
Potential Drug Interactions With DOVATO
Established and Other Potentially Significant Drug-to-Drug Interactions
Avoid |
|
---|---|
Contraindicated |
|
Dofetilide |
|
Avoid Coadministration |
|
Agent |
Recommendations |
Oxcarbazepine Phenobarbital Phenytoin St. John’s wort (Hypericum perforatum) |
Avoid coadministration with DOVATO because there are insufficient data to make dosing recommendations |
Sorbitol |
When possible, avoid use of sorbitol-containing medicines with DOVATO |
Because DOVATO is a complete regimen, coadministration with other ARVs for the treatment of HIV-1 infection is not recommended.
Dosing Adjustments and Considerations |
|
---|---|
Agent |
Recommendations |
Carbamazepine or rifampin |
An additional dolutegravir 50-mg dose should be taken, separated by 12 hours from DOVATO |
Metformin |
Refer to the Prescribing Information for metformin for assessing the benefit and risk of concomitant use of DOVATO and metformin |
Medications containing polyvalent cations (eg, Mg or Al): cation-containing antacids or laxatives, sucralfate, or buffered medications |
Administer DOVATO 2 hours before or 6 hours after taking medications containing polyvalent cations |
Oral calcium and iron supplements, including multivitamins containing calcium or iron |
When taken with food, DOVATO and supplements or multivitamins containing calcium or iron can be taken at the same time. Under fasting conditions, DOVATO should be taken 2 hours before or 6 hours after taking supplements containing calcium or iron |
Dalfampridine |
Elevated levels of dalfampridine increase the risk of seizures. The potential benefits of taking dalfampridine concurrently with DOVATO should be considered against the risk of seizures in these patients |
Please see Section 7 of the full Prescribing Information for additional drug interaction information.
No Expected Dosing Adjustments1-7
Dolutegravir and lamivudine, components of DOVATO, have no clinically relevant effects on the pharmacokinetics of the following agents.
Based on available pharmacokinetics drug interaction studies |
---|
|
|
|
|
|
Based on pharmacokinetics, metabolic pathways, and/or available drug interaction studies |
---|
Hepatitis C drugs, including: |
|
|
|
|
|
|
|
*Norelgestromin is the active metabolite of norgestimate, and no drug interaction is expected with norgestimate.8
SEE IF YOUR PATIENTS CAN SAVE ON DOVATO
Al=aluminum; ARV=antiretroviral; Mg=magnesium; NDC=National Drug Code.
References:
1. AIDSinfo: Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. US Department of Health and Human Services. Accessed February 7, 2023. https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-arv/guidelines-adult-adolescent-arv.pdf
2. American Association for the Study of Liver Diseases and Infectious Diseases Society of America. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. Updated May 24, 2018. Accessed March 2, 2022. https://www.hcvguidelines.org/unique-populations/hiv-hcv
3. Harvoni [package insert]. Foster City, CA: Gilead Sciences, Inc.; 2020.
4. Zepatier [package insert]. Whitehouse Station, NJ: Merck & Co, Inc.; 2022.
5. Viekira Pak [package insert]. North Chicago, IL: AbbVie, Inc.; 2019.
6. Vosevi [package insert]. Foster City, CA: Gilead Sciences, Inc.; 2019.
7. Mavyret [package insert]. North Chicago, IL: AbbVie, Inc.; 2021.
8. Song IH, Borland J, Chen S, Wajima T, Peppercorn AF, Piscitelli SC. Dolutegravir has no effect on the pharmacokinetics of oral contraceptives with norgestimate and ethinyl estradiol. Ann Pharmacother. 2015;49(7):784-789.
DLLWCNT230042 January 2024